GETI.B

210.8

-0.05%↓

CAMX

602

-0.41%↓

BIOAB

308.4

-3.08%↓

EKTA.B

57.05

+2.24%↑

VITR

141.2

+1.66%↑

GETI.B

210.8

-0.05%↓

CAMX

602

-0.41%↓

BIOAB

308.4

-3.08%↓

EKTA.B

57.05

+2.24%↑

VITR

141.2

+1.66%↑

GETI.B

210.8

-0.05%↓

CAMX

602

-0.41%↓

BIOAB

308.4

-3.08%↓

EKTA.B

57.05

+2.24%↑

VITR

141.2

+1.66%↑

GETI.B

210.8

-0.05%↓

CAMX

602

-0.41%↓

BIOAB

308.4

-3.08%↓

EKTA.B

57.05

+2.24%↑

VITR

141.2

+1.66%↑

GETI.B

210.8

-0.05%↓

CAMX

602

-0.41%↓

BIOAB

308.4

-3.08%↓

EKTA.B

57.05

+2.24%↑

VITR

141.2

+1.66%↑

Home・Akcijų sąrašas・Vivesto AB

Vivesto AB

Uždarymo kaina

0.22

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.22

Max

0.22

Pagrindiniai rodikliai
By Trading Economics
Pajamos	2.3M -7.2M
Pelnas, tenkantis vienai akcijai	-0.013
Darbuotojai	4

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-4.4M 74M
Ankstesnė atidarymo kaina	0.22
Ankstesnė uždarymo kaina	0.22

Vivesto AB Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-04 20:41; UTC

Uždarbis

Pagrindinės rinkos jėgos

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

2025-12-04 18:14; UTC

Įsigijimai, susijungimai, perėmimai

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

2025-12-04 17:43; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

2025-12-04 17:01; UTC

Uždarbis

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

2025-12-04 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

2025-12-04 23:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-04 21:54; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-04 21:54; UTC

Rinkos pokalbiai

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

2025-12-04 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-12-04 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-04 21:48; UTC

Rinkos pokalbiai

Scales Hits Mark With Earnings Guidance -- Market Talk

2025-12-04 21:37; UTC

Uždarbis

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

2025-12-04 21:36; UTC

Uždarbis

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

2025-12-04 20:15; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-04 20:15; UTC

Rinkos pokalbiai

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

2025-12-04 20:04; UTC

Rinkos pokalbiai

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

2025-12-04 19:54; UTC

Rinkos pokalbiai

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

2025-12-04 19:44; UTC

Įsigijimai, susijungimai, perėmimai

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

2025-12-04 19:44; UTC

Įsigijimai, susijungimai, perėmimai

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

2025-12-04 19:44; UTC

Įsigijimai, susijungimai, perėmimai

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

2025-12-04 19:33; UTC

Rinkos pokalbiai

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

2025-12-04 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

2025-12-04 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

2025-12-04 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

2025-12-04 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

2025-12-04 18:58; UTC

Rinkos pokalbiai

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

2025-12-04 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-04 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-12-04 16:41; UTC

Rinkos pokalbiai

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

2025-12-04 16:33; UTC

Rinkos pokalbiai

Uždarbis

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Akcijų palyginimas

Kainos pokytis

Vivesto AB Prognozė

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.